• Highlights from CIC 2023

  • May 15 2023
  • Length: 37 mins
  • Podcast

Highlights from CIC 2023

  • Summary

  • ๐ŸŽ™๏ธ๐ŸŽ™๏ธ๐ŸŽ™๏ธ ๏ธ ๐๐ข๐  ๐๐ž๐ฐ๐ฌ ๐Ÿ๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐ก๐ž๐š๐ซ๐ญ ๐จ๐Ÿ ๐‚๐š๐ง๐š๐๐š'๐ฌ ๐œ๐š๐ฉ๐ข๐ญ๐š๐ฅ! ๐Ÿ๐–๐ž'๐ซ๐ž ๐ญ๐ก๐ซ๐ข๐ฅ๐ฅ๐ž๐ ๐ญ๐จ ๐š๐ง๐ง๐จ๐ฎ๐ง๐œ๐ž ๐ญ๐ก๐š๐ญ ๐ฐ๐ž'๐ซ๐ž ๐ฅ๐š๐ฎ๐ง๐œ๐ก๐ข๐ง๐  ๐š ๐ฉ๐จ๐๐œ๐š๐ฌ๐ญ ๐ฌ๐ž๐ซ๐ข๐ž๐ฌ ๐ฌ๐ญ๐ซ๐š๐ข๐ ๐ก๐ญ ๐Ÿ๐ซ๐จ๐ฆ ๐Ž๐ญ๐ญ๐š๐ฐ๐š, ๐›๐ซ๐จ๐š๐๐œ๐š๐ฌ๐ญ๐ข๐ง๐  ๐š๐ฅ๐ฅ ๐ญ๐ก๐ž ๐š๐œ๐ญ๐ข๐จ๐ง ๐š๐ง๐ ๐ข๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ ๐Ÿ๐ซ๐จ๐ฆ ๐‚๐ˆ๐‚ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ‘.๐“๐ก๐ข๐ฌ ๐ž๐ฉ๐ข๐ฌ๐จ๐๐ž ๐ข๐ฌย ๐ฒ๐จ๐ฎ๐ซ ๐š๐ฅ๐ฅ-๐š๐œ๐œ๐ž๐ฌ๐ฌ ๐ฉ๐š๐ฌ๐ฌ ๐ญ๐จ ๐š ๐œ๐ฎ๐ซ๐š๐ญ๐ž๐ ๐ฌ๐ž๐ฅ๐ž๐œ๐ญ๐ข๐จ๐ง ๐จ๐Ÿ ๐Ÿ‘ ๐ฌ๐ก๐จ๐ซ๐ญ ๐œ๐จ๐ง๐ฏ๐ž๐ซ๐ฌ๐š๐ญ๐ข๐จ๐ง๐ฌ ๐ฐ๐ข๐ญ๐ก ๐œ๐ฅ๐ข๐ง๐ข๐œ๐ข๐š๐ง ๐ญ๐ก๐จ๐ฎ๐ ๐ก๐ญ ๐ฅ๐ž๐š๐๐ž๐ซ๐ฌ ย ๐š๐ง๐ ๐ ๐š๐ฆ๐ž ๐œ๐ก๐š๐ง๐ ๐ž๐ซ๐ฌ ๐ฐ๐ก๐จ ๐š๐ซ๐ž ๐ฌ๐ก๐š๐ฉ๐ข๐ง๐  ๐ญ๐ก๐ž ๐Ÿ๐ฎ๐ญ๐ฎ๐ซ๐ž ๐จ๐Ÿ ๐ฉ๐ฎ๐›๐ฅ๐ข๐œ ๐ก๐ž๐š๐ฅ๐ญ๐ก ๐š๐ง๐ ๐›๐ž๐ฒ๐จ๐ง๐.๐™๐™ช๐™ฃ๐™š ๐™ž๐™ฃ, ๐™ฉ๐™ช๐™ง๐™ฃ ๐™ช๐™ฅ ๐™ฉ๐™๐™š ๐™ซ๐™ค๐™ก๐™ช๐™ข๐™š, ๐™–๐™ฃ๐™™ ๐™ฉ๐™ง๐™–๐™ฃ๐™จ๐™›๐™ค๐™ง๐™ข ๐™ฉ๐™ค๐™œ๐™š๐™ฉ๐™๐™š๐™ง.ย ๐ŸŽง #๐˜พ๐™„๐˜พ2023 #๐™‹๐™ค๐™™๐™˜๐™–๐™จ๐™ฉ #๐™Š๐™ฉ๐™ฉ๐™–๐™ฌ๐™–ย ย ๐ŸŽ™๏ธ๐ŸŽ™๏ธ๐ŸŽ™๏ธ MINI EPISODE 1: A Conversation with Dr.Sonia Anand MD, PhD, FRCPC๐Ÿ’ก ๐Ÿ’ก ๐Ÿ’กEnsuring immunization of structurally disadvantaged populations: Black People and other people of colourย Podcast Learning objectivesโ€ข Describe how race-disaggregated data can allow for more targeted, community-specific interventions. ย โ€ข Apply novel community-specific work to engage communities to support immunization. ย โ€ข Illustrate how anti-Black racism presents a pervasive barrier to engaging with preventive health care initiatives.ย For this mini podcast, we delve into how historical and systemic racism creates hurdles not only in understanding vaccine coverage discrepancies in Canada, but also in crafting effective, nuanced responses. We spotlight the distinctive obstacles Black and Asian communities in Canada have faced in accessing vaccines, both amidst the pandemic and prior to it. In the absence of detailed race-specific data for monitoring diseases preventable by vaccines and tracking vaccination rates, it is difficult to adequately cater to marginalized communities who face systemic barriers to healthcare access, including vaccinations. Dr.Anand unpacks this complex issue.ย About Dr.Sonia Anand MD, PhD, FRCPCProfessor of Medicine and Epidemiology, McMasterSenior Scientist Population Health Research InstituteTier 1 Canada Research Chair in Ethnic Diversity and Cardiovascular DiseaseHeart and Stroke Chair in Population HealthAssociate Chair of Equity and Diversity, Department of MedicineDirector of Chanchlani Research Centreย Dr. Sonia Anand is a professor in the Department of Medicine, and the Director of the Population Genomics Program, at McMaster. She is also a senior scientist at the Population Health Research Institute at Hamilton Health Sciences. Dr. Anand holds a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease, and the Heart and Stroke Foundation of Ontario/Michael G. DeGroote Chair in Population Health Research. In 2010, Dr. Anand was named among the top 100 women by the Womenโ€™s Executive Network for her accomplishments in research and medicine. Her current research focuses on environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease.ย ๐ŸŽ™๏ธ๐ŸŽ™๏ธ๐ŸŽ™๏ธ MINI EPISODE 2: A Conversation with ย Dr.Wayne Ghesquiere MD, FRCPC ย ๐Ÿ’ก ๐Ÿ’ก ๐Ÿ’กLong-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination ย ย Podcast Learning objectives ย โ€ข Discuss the interim efficacy of the adjuvanted recombinant zoster vaccine approximately 10 years post-vaccination.โ€ข Explain the immunogenicity of the adjuvanted recombinant zoster vaccine and how it contributes to its long-term protection against herpes zoster.โ€ข Evaluate the safety profile of the adjuvanted recombinant zoster vaccine based on data collected over approximately 10 years.โ€ข Analyze the significance of these interim results in the context of long-term vaccine strategies against herpes zoster.โ€ข Incorporate the provided insights into clinical practice and future research regarding herpes zoster vaccination strategies.โ€ข Communicate effectively to patients about the long-term benefits and safety of the adjuvanted recombinant zoster ...
    Show More Show Less

What listeners say about Highlights from CIC 2023

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.